The U.S. Food and Drug Administration (FDA) has approved Ziextenzo (pegfilgrastim-bmez), the 24th biosimilar approval in the U.S.
The Centers for Medicare and Medicaid Services (CMS) has launched the Healthy Adult Opportunity (HAO) optional demonstration initiative to give states tools to design innovative health coverage programs for adult beneficiaries, while holding states accountable for results and maintaining strong protections for the most at-risk populations.
The Centers for Medicare and Medicaid Services (CMS) finalized a decision to cover acupuncture for Medicare patients with chronic low back pain.
New rule requires hospitals to share previously obscured price information, including discounts for cash-paying patients and rates negotiated with insurers.
The U.S. Food and Drug Administration (FDA) is taking critical actions to advance development of novel coronavirus medical countermeasures.
The awards establish and provide up to seven years of support for three Immune Mechanisms of Protection Against Mycobacterium Tuberculosis (IMPAc-TB) Centers to elucidate the immune responses needed to protect against Mtb infection.
The National Institutes of Health (NIH) is conducting an early-stage clinical trial to evaluate the safety and efficacy of two licensed seasonal influenza vaccines administered with or without novel adjuvants.
Kedrion Biopharma has created the free, easy-to-use KEDRAB Dose Calculator to help healthcare providers treat rabies exposures.
Octapharma introduced its newest product, Cutaquig (immune globulin subcutaneous [human] 16.5% solution) at the Immune Deficiency Foundation (IDF) National Conference in June.
A revised product label for Octapharma USA’s Octaplas (pooled plasma [human] solvent/detergent treated solution for intravenous infusion) to treat critically ill pediatric patients who require replacement of multiple coagulation factors has been approved by the U.S. Food and Drug Administration (FDA).
A new study shows the HPV vaccine is far more effective than expected, with benefits extending beyond those who receive the vaccine.
A previously unknown autoimmune muscle disease involving sudden onset of debilitating muscle pain and weakness has been identified by researchers at Washington University School of Medicine in St. Louis, Mo.
